Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Gastroenterology

13.05.2024

Obesity and Esophageal Dysfunction

verfasst von: Khushboo Gala, MBBS, Karthik Ravi, MD

Erschienen in: Current Treatment Options in Gastroenterology

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Obesity and related comorbidities are on the rise, with trends showing that nearly half of the United States population will be obese by 2030. This review focuses on the pathophysiology of esophageal disorders in patients with obesity as well as treatment considerations for obesity in patients with esophageal disorders.

Recent Findings

Gastroesophageal reflux disease (GERD) is prevalent in approximately 20% of patients with obesity and is associated with multiple underlying anatomic risk factors. In addition, systemic and paracrine proinflammatory effects mediated by visceral adipose tissue also contribute to the development of GERD-related complications such as erosive esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Esophageal dysmotility is also common in obesity, although with varying clinical impact as the majority of patients are asymptomatic. Although data regarding laparoscopic sleeve gastrectomy and GERD is conflicting, Roux-en-Y gastric bypass is considered the preferred surgical approach for obesity in patients with GERD. Recent data signal that newer anti-obesity medications like glucagon-like peptide 1 (GLP-1) agonists may lead to increased GERD and related complications; however, data on this subject is limited.

Summary

Esophageal dysfunction is prevalent in patients with obesity and should be carefully evaluated prior to considering treatment for obesity such as bariatric surgery or antiobesity medications.
Literatur
1.
Alfaris N, et al. Global Impact of Obesity. Gastroenterol Clin North Am. 2023;52(2):277–93.PubMedCrossRef
2.
Ward ZJ, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019;381(25):2440–50.PubMedCrossRef
3.
4.
Singh S, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(11):1399-1412 e7.PubMedCrossRef
5.
Abdallah J, et al. The relationship between length of Barrett’s oesophagus mucosa and body mass index. Aliment Pharmacol Ther. 2015;41(1):137–44.PubMedCrossRef
6.
Corley DA, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133(1):34–41.PubMedCrossRef
7.
8.
Schlottmann F, Dreifuss NH, Patti MG. Obesity and esophageal cancer: GERD, Barrett s esophagus, and molecular carcinogenic pathways. Expert Rev Gastroenterol Hepatol. 2020;14(6):425–33.PubMedCrossRef
9.
Dirac MA, Safiri S, Tsoi D, Adedoyin RA, Afshin A, Akhlaghi N, Alahdab F, Almulhim AM, Amini S, Ausloos F, Bacha U. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(6):561–81.CrossRef
10.
Eusebi LH, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–40.PubMedCrossRef
11.
Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199–211.PubMedCrossRef
12.
El-Serag HB, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol. 2005;100(6):1243–50.PubMedCrossRef
13.
14.
Ness-Jensen E, et al. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol. 2013;108(3):376–82.PubMedCrossRef
15.
Pandolfino JE, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006;130(3):639–49.PubMedCrossRef
16.
Varela JE, Hinojosa M, Nguyen N. Correlations between intra-abdominal pressure and obesity-related co-morbidities. Surg Obes Relat Dis. 2009;5(5):524–8.PubMedCrossRef
17.
El-Serag HB, et al. Anthropometric correlates of intragastric pressure. Scand J Gastroenterol. 2006;41(8):887–91.PubMedCrossRef
18.
Che F, et al. Prevalence of hiatal hernia in the morbidly obese. Surg Obes Relat Dis. 2013;9(6):920–4.PubMedCrossRef
19.
de Vries DR, et al. Gastroesophageal pressure gradients in gastroesophageal reflux disease: relations with hiatal hernia, body mass index, and esophageal acid exposure. Am J Gastroenterol. 2008;103(6):1349–54.PubMedCrossRef
20.
Suter M, et al. Gastro-esophageal reflux and esophageal motility disorders in morbidly obese patients. Obes Surg. 2004;14(7):959–66.PubMedCrossRef
21.
22.
Wu JC, et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology. 2007;132(3):883–9.PubMedCrossRef
23.
Schneider JH, et al. Transient lower esophageal sphincter relaxation in morbid obesity. Obes Surg. 2009;19(5):595–600.PubMedCrossRef
24.
25.
Koppman JS, et al. Esophageal motility disorders in the morbidly obese population. Surg Endosc. 2007;21(5):761–4.PubMedCrossRef
26.
Cote-Daigneault J, et al. High prevalence of esophageal dysmotility in asymptomatic obese patients. Can J Gastroenterol Hepatol. 2014;28(6):311–4.PubMedPubMedCentralCrossRef
27.
Rogers BD, et al. Higher Esophageal Symptom Burden in Obese Subjects Results From Increased Esophageal Acid Exposure and Not From Dysmotility. Clin Gastroenterol Hepatol. 2020;18(8):1719–26.PubMedCrossRef
28.
Fox M, et al. The effects of dietary fat and calorie density on esophageal acid exposure and reflux symptoms. Clin Gastroenterol Hepatol. 2007;5(4):439–44.PubMedCrossRef
29.
Thrift AP. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol. 2021;18(6):432–43.PubMedCrossRef
30.
Lynch KL. Is Obesity Associated with Barrett’s Esophagus and Esophageal Adenocarcinoma? Gastroenterol Clin North Am. 2016;45(4):615–24.PubMedCrossRef
31.
El-Serag HB, et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett’s oesophagus: a case-control study. Gut. 2014;63(2):220–9.PubMedCrossRef
32.
Kamat P, et al. Exploring the association between elevated body mass index and Barrett’s esophagus: a systematic review and meta-analysis. Ann Thorac Surg. 2009;87(2):655–62.PubMedCrossRef
33.
Cook MB, et al. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett’s esophagus. Am J Gastroenterol. 2008;103(2):292–300.PubMedCrossRef
34.
Qumseya B, et al. Prevalence of Barrett’s esophagus in obese patients undergoing pre-bariatric surgery evaluation: a systematic review and meta-analysis. Endoscopy. 2020;52(7):537–47.PubMedCrossRef
35.
Kubo A, et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett’s oesophagus: a pooled analysis from the international BEACON consortium. Gut. 2013;62(12):1684–91.PubMedCrossRef
36.
Hoyo C, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol. 2012;41(6):1706–18.PubMedPubMedCentralCrossRef
37.
Lahmann PH, et al. Body mass index, long-term weight change, and esophageal squamous cell carcinoma: is the inverse association modified by smoking status? Cancer. 2012;118(7):1901–9.PubMedCrossRef
38.
Avgerinos KI, et al. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–35.PubMedCrossRef
39.
Perrini S, et al. Differences in gene expression and cytokine release profiles highlight the heterogeneity of distinct subsets of adipose tissue-derived stem cells in the subcutaneous and visceral adipose tissue in humans. PLoS ONE. 2013;8(3):e57892.PubMedPubMedCentralCrossRef
40.
Ryan AM, et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol. 2011;35(4):309–19.PubMedCrossRef
41.
Rubenstein JH, et al. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett’s esophagus. Gastroenterology. 2013;145(6):1237-44 e1-5.PubMedCrossRef
42.
43.
Paris S, et al. Obesity and its effects on the esophageal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. 2021;321(3):G335–43.PubMedCrossRef
44.
Blevins CH, et al. Obesity and GERD impair esophageal epithelial permeability through 2 distinct mechanisms. Neurogastroenterol Motil. 2018;30(10):e13403.PubMedCrossRef
45.
Cook MB, et al. Association between circulating levels of sex steroid hormones and Barrett’s esophagus in men: a case-control analysis. Clin Gastroenterol Hepatol. 2015;13(4):673–82.PubMedCrossRef
46.
Gall A, et al. Bacterial Composition of the Human Upper Gastrointestinal Tract Microbiome Is Dynamic and Associated with Genomic Instability in a Barrett’s Esophagus Cohort. PLoS ONE. 2015;10(6):e0129055.PubMedPubMedCentralCrossRef
47.
Hong D, et al. Manometric abnormalities and gastroesophageal reflux disease in the morbidly obese. Obes Surg. 2004;14(6):744–9.PubMedCrossRef
48.
Yarandi SS, et al. Diverse roles of leptin in the gastrointestinal tract: modulation of motility, absorption, growth, and inflammation. Nutrition. 2011;27(3):269–75.PubMedCrossRef
49.
Cote-Daigneault J, et al. Plasma leptin concentrations and esophageal hypomotility in obese patients. Can J Gastroenterol Hepatol. 2015;29(1):49–51.PubMedPubMedCentralCrossRef
50.
Miron I, Dumitrascu DL. Gastrointestinal Motility Disorders in Obesity. Acta Endocrinol (Buchar). 2019;15(4):497–504.PubMedCrossRef
51.
Shah, K., F. Raffa, and R.D. Naik, Chapter 5 - Obesity and esophageal dysmotility, in Obesity and Esophageal Disorders, D. Patel, et al., Editors. 2022, Academic Press. p. 61–76.
52.
Welbourn R, et al. Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Fourth IFSO Global Registry Report 2018. Obes Surg. 2019;29(3):782–95.PubMedCrossRef
53.
Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic Bariatric and Metabolic Therapies: New and Emerging Technologies. Gastroenterology. 2017;152(7):1791–801.PubMedCrossRef
54.
Clapp B, et al. American Society for Metabolic and Bariatric Surgery 2020 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis. 2022;18(9):1134–40.PubMedCrossRef
55.
Rebecchi F, et al. Gastroesophageal reflux disease and laparoscopic sleeve gastrectomy: a physiopathologic evaluation. Ann Surg. 2014;260(5):909–14.PubMedCrossRef
56.
Elkassem S. Gastroesophageal Reflux Disease, Esophagitis, and Barrett’s Esophagus 3 to 4 Years Post Sleeve Gastrectomy. Obes Surg. 2021;31(12):5148–55.PubMedCrossRef
57.
Yeung KTD, et al. Does Sleeve Gastrectomy Expose the Distal Esophagus to Severe Reflux?: A Systematic Review and Meta-analysis. Ann Surg. 2020;271(2):257–65.PubMedCrossRef
58.
Ferrer JV, et al. High rate of de novo esophagitis 5 years after sleeve gastrectomy: a prospective multicenter study in Spain. Surg Obes Relat Dis. 2022;18(4):546–54.PubMedCrossRef
59.
Yehoshua RT, et al. Laparoscopic sleeve gastrectomy–volume and pressure assessment. Obes Surg. 2008;18(9):1083–8.PubMedCrossRef
60.
61.
Greenan G, Rogers BD, Gyawali CP. Proximal Gastric Pressurization After Sleeve Gastrectomy Associates With Gastroesophageal Reflux. Am J Gastroenterol. 2023;118(12):2148–56.PubMedCrossRef
62.
Coupaye M, et al. Gastroesophageal Reflux After Sleeve Gastrectomy: a Prospective Mechanistic Study. Obes Surg. 2018;28(3):838–45.PubMedCrossRef
63.
Coupaye M, et al. Endoscopic Follow-Up Between 3 and 7 Years After Sleeve Gastrectomy Reveals Antral Reactive Gastropathy but no Barrett’s Esophagus. Obes Surg. 2023;33(10):3112–9.PubMedCrossRef
64.
Hajibandeh S, et al. Meta-analysis of Long-term De Novo Acid Reflux-Related Outcomes Following Sleeve Gastrectomy: Evidence Against the Need for Routine Postoperative Endoscopic Surveillance. Curr Obes Rep. 2023;12(3):395–405.PubMedCrossRef
65.
Dias E, et al. Prevalence and Clinical Impact of Abnormal Findings in Routine Upper Digestive Endoscopy Before Bariatric Surgery. Chirurgia (Bucur). 2022;117(6):681–8.PubMedCrossRef
66.
67.
Yadlapati R, et al. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol. 2022;20(5):984-994 e1.PubMedPubMedCentralCrossRef
68.
Bellorin O, et al. Robotic-assisted approaches to GERD following sleeve gastrectomy. Surg Endosc. 2021;35(6):3033–9.PubMedCrossRef
69.
Indja B, Chan DL, Talbot ML. Hiatal reconstruction is safe and effective for control of reflux after laparoscopic sleeve gastrectomy. BMC Surg. 2022;22(1):347.PubMedPubMedCentralCrossRef
70.
Hathorn KE, Jirapinyo P, Thompson CC. Endoscopic management of gastroesophageal reflux disease after sleeve gastrectomy by use of the antireflux mucosectomy procedure. VideoGIE. 2019;4(6):251–3.PubMedPubMedCentralCrossRef
71.
Eisenberg D, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2022;18(12):1345–56.PubMedCrossRef
72.
73.
de Jong JR, et al. Effects of adjustable gastric banding on gastroesophageal reflux and esophageal motility: a systematic review. Obes Rev. 2010;11(4):297–305.PubMedCrossRef
74.
Himpens J, Dapri G, Cadiere GB. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. Obes Surg. 2006;16(11):1450–6.PubMedCrossRef
75.
Elias K, Hedberg J, Sundbom M. Prevalence and impact of acid-related symptoms and diarrhea in patients undergoing Roux-en-Y gastric bypass, sleeve gastrectomy, and biliopancreatic diversion with duodenal switch. Surg Obes Relat Dis. 2020;16(4):520–7.PubMedCrossRef
76.
Moller F, et al. Long-term Follow-up 15 Years After Duodenal Switch or Gastric Bypass for Super Obesity: a Randomized Controlled Trial. Obes Surg. 2023;33(10):2981–90.PubMedPubMedCentralCrossRef
77.
Esparham A, et al. The Efficacy and Safety of Laparoscopic Single-Anastomosis Duodeno-ileostomy with Sleeve Gastrectomy (SADI-S) in Mid- and Long-Term Follow-Up: a Systematic Review. Obes Surg. 2023;33(12):4070–9.PubMedCrossRef
78.
Beran A, et al. Comparative Effectiveness and Safety Between Endoscopic Sleeve Gastroplasty and Laparoscopic Sleeve Gastrectomy: a Meta-analysis of 6775 Individuals with Obesity. Obes Surg. 2022;32(11):3504–12.PubMedCrossRef
79.
Force ABET, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425-38 e5.CrossRef
80.
Boules M, et al. Achalasia After Bariatric Surgery. J Laparoendosc Adv Surg Tech A. 2016;26(6):428–32.PubMedCrossRef
81.
Miller AT, et al. Postobesity Surgery Esophageal Dysfunction: A Combined Cross-Sectional Prevalence Study and Retrospective Analysis. Am J Gastroenterol. 2020;115(10):1669–80.PubMedCrossRef
82.
83.
Ravi K, Sweetser S, Katzka DA. Pseudoachalasia secondary to bariatric surgery. Dis Esophagus. 2016;29(8):992–5.PubMedCrossRef
84.
Sodhi M, et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795–7.PubMedPubMedCentralCrossRef
85.
Liu BD, et al. Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study. Gut. 2024;73(2):246–54.PubMedCrossRef
86.
Haddad JD, Shah SL. Medical Management of Obesity as it Affects Reflux. Foregut. 2021;1(4):328–35.CrossRef
Metadaten
Titel
Obesity and Esophageal Dysfunction
verfasst von
Khushboo Gala, MBBS
Karthik Ravi, MD
Publikationsdatum
13.05.2024
Verlag
Springer US
Erschienen in
Current Treatment Options in Gastroenterology
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-024-00450-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise